Cadila Pharmaceuticals Ltd, based in India, is a pharmaceutical company that stands out with its certifications from FDA and EDQM.
One of their notable products is O-DESMETHYL VENLAFAXINE SUCCINATE, with a corresponding US DMF Number 22472.
Remarkably, this DMF maintains an Active status since its submission on January 22, 2009, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of October 08, 2015, and payment made on March 16, 2015, indicating their dedication to facilitating drug approvals, Categorized as Type II